TerminatedPhase 2NCT05667662

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Studying Allergic bronchopulmonary aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pulmatrix Inc.
Principal Investigator
Chris Cabell, MD
Pulmatrix Inc.
Intervention
Itraconazole Powder(drug)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
20232024

Study locations (18)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05667662 on ClinicalTrials.gov

Other trials for Allergic bronchopulmonary aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Allergic bronchopulmonary aspergillosis

← Back to all trials